Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bjc.2014.290 http://scihub22266oqcxt.onion/10.1038/bjc.2014.290 C4102944!4102944!24901237     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Cancer 2014 ; 111 (2): 272-80 Nephropedia Template TP {{tp|p=24901237|t=2014. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma |pdf=|usr=}}{{24901237}} gab.com Text Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma JO: Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24901237 #FOAvip Background:: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1? inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitumour activity as monotherapy or combined with erlotinib. Methods:: Patients with solid tumours received ficlatuzumab 2, 5, 10 or 20?mg?kg?1 intravenously every 2 weeks (q2w). Additional patients were treated at the RP2D erlotinib. Results:: Forty-one patients enrolled at doses ?20?mg?kg?1. Common adverse events (AEs) included peripheral oedema, fatigue and nausea. Three patients experienced grade ?3 treatment-related hyperkalaemia/hypokalaemia, diarrhoea or fatigue. Best overall response (44%) was stable disease (SD); median duration was 5.5 months (0.4?18.7 months). One patient has been on therapy with SD for >4 years. Pharmacokinetics of ficlatuzumab showed low clearance (0.17?0.26?ml?h?1?kg?1), a half-life of 6.8?9.4 days and dose-proportional exposure. Ficlatuzumab/erlotinib had no impact on the PK of either agent. No ADAs were detected. Ficlatuzumab increased serum HGF levels. Conclusions:: Recommended phase II dose is 20?mg?kg?1 q2w for ficlatuzumab monotherapy or with erlotinib. Preliminary antitumour activity and manageable AEs were observed. Pharmacokinetics were dose-proportional and consistent with other IgG therapeutics. Ficlatuzumab was not immunogenic, and serum HGF was a potential PD marker. Twit Text FOAVip Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma ????Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24901237 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24901237 #FOAvip English Wikipedia <ref>{{Cite pmid|24901237}}</ref> Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma #MMPMID24901237 Patnaik A; Weiss GJ; Papadopoulos KP; Hofmeister CC; Tibes R; Tolcher A; Isaacs R; Jac J; Han M; Payumo FC; Cotreau MM; Ramanathan RK Br J Cancer 2014[Jul]; 111 (2): 272-80 PMID24901237show ga Background:: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1? inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitumour activity as monotherapy or combined with erlotinib. Methods:: Patients with solid tumours received ficlatuzumab 2, 5, 10 or 20?mg?kg?1 intravenously every 2 weeks (q2w). Additional patients were treated at the RP2D erlotinib. Results:: Forty-one patients enrolled at doses ?20?mg?kg?1. Common adverse events (AEs) included peripheral oedema, fatigue and nausea. Three patients experienced grade ?3 treatment-related hyperkalaemia/hypokalaemia, diarrhoea or fatigue. Best overall response (44%) was stable disease (SD); median duration was 5.5 months (0.4?18.7 months). One patient has been on therapy with SD for >4 years. Pharmacokinetics of ficlatuzumab showed low clearance (0.17?0.26?ml?h?1?kg?1), a half-life of 6.8?9.4 days and dose-proportional exposure. Ficlatuzumab/erlotinib had no impact on the PK of either agent. No ADAs were detected. Ficlatuzumab increased serum HGF levels. Conclusions:: Recommended phase II dose is 20?mg?kg?1 q2w for ficlatuzumab monotherapy or with erlotinib. Preliminary antitumour activity and manageable AEs were observed. Pharmacokinetics were dose-proportional and consistent with other IgG therapeutics. Ficlatuzumab was not immunogenic, and serum HGF was a potential PD marker. äPhase I ficlatuzumab monotherapy or with erlotinib for refractory adva(epmc).pdf DeepDyve Pubget Overpricing